Nanobac Pharmaceuticals
WKN: 912641 / ISIN: US63007M1027Investiert in den Multi-Blockbuster!
20.10.06 12:01
#1
Nukem
Investiert in den Multi-Blockbuster!
NANOBAC PHARMACEUTICALS
Wkn: 912641
Berlin/USA
Herz-Kreislauf Erkrankungen, Gefäßablagerungen sind auf dem Gesundheitssektor die lukrativsten Märkte. Hier geht es nicht um Nischenmedikamente, sondern um Volkskrankheiten mit einer sehr großen Zahl von Betroffenen.
Nanobac geht infektiösen Erregern, welche für Nieren- und Gallensteine, Arteriosklerose und Gefäßablagerungen verantwortlich gemacht werden mit Nanopartikeln ans Leder.
Nanobac ist der Meinung dass man die Lösung gefunden hat, den Auslöser effektiv zu bekämpfen. Der Markt ist mehr als nur gigantisch, da man mit einem solchen Lösungsansatz gleich eine ganze Reihe von Blockbustern schaffen würde. Alleine diese Phantasie wird meiner Meinung nach, dem Titel in den nächsten Wochen und Monaten Auftrieb geben.
Mehr Phantasie als bei Nanobac gibt es nicht. Mir ist kein Pharmatitel und kein Biotechnologie-Titel bekannt, der die Lösung für so viele Blockbuster in der Tasche hätte. Sollte Nanobac Erfolg haben, kann man sich kaum vorstellen, wo der Kurs dann stehen wird.
Einige NNBP Shares sollte man meiner Meinung nach im Depot haben. Lt. Mr. Silver, Director of Research for Wall Street Resources ist Nanobac`s potentieller Markt 500 Mrd. Dollar schwer. 69% aller OS Aktien werden vom Nanobac-Team selbst gehalten. Quelle:
http://www.wallstreetresources.net/pdf/fc/NNBP.pdf
Auch ohne Erfolgsmeldung wird der Titel meiner Meinung nach, aufgrund der enormen Ertragsmöglichkeiten in einem kurzen Zeitfenster bis auf 50-60 Cent laufen. (Börse handelt die Zukunft).
Der Stochastik generiert ein Kaufsignal. Die Bullen gewinnen an Oberwasser.
Mit American Health Associates wurde eine Übereinkunft geschlossen, um o. g. Testverfahren durchzuführen.
http://biz.yahoo.com/bw/061004/20061004005580.html?.v=1
Mr. Paul Silver, Director of Research for Wall Street Resources, Inc., which contains a short-term target value for NNBP of $0.91 per share.
http://biz.yahoo.com/bw/060912/20060912005464.html?.v=1
http://www.wallstreetresources.net/pdf/fc/NNBP.pdf
Das ist keine Kauf- oder Verkaufsempfehlung. Aktien können fallen oder steigen. Bei Aktienanlagen ist auch in manchen Fällen ein Totalverlust möglich. Übersetzungsfehler behalte ich mir vor, da meine Muttersprache Deutsch ist. Alle Angaben ohne Gewähr. Quellen bitte selbst nochmal nachlesen.
Wkn: 912641
Berlin/USA
Herz-Kreislauf Erkrankungen, Gefäßablagerungen sind auf dem Gesundheitssektor die lukrativsten Märkte. Hier geht es nicht um Nischenmedikamente, sondern um Volkskrankheiten mit einer sehr großen Zahl von Betroffenen.
Nanobac geht infektiösen Erregern, welche für Nieren- und Gallensteine, Arteriosklerose und Gefäßablagerungen verantwortlich gemacht werden mit Nanopartikeln ans Leder.
Nanobac ist der Meinung dass man die Lösung gefunden hat, den Auslöser effektiv zu bekämpfen. Der Markt ist mehr als nur gigantisch, da man mit einem solchen Lösungsansatz gleich eine ganze Reihe von Blockbustern schaffen würde. Alleine diese Phantasie wird meiner Meinung nach, dem Titel in den nächsten Wochen und Monaten Auftrieb geben.
Mehr Phantasie als bei Nanobac gibt es nicht. Mir ist kein Pharmatitel und kein Biotechnologie-Titel bekannt, der die Lösung für so viele Blockbuster in der Tasche hätte. Sollte Nanobac Erfolg haben, kann man sich kaum vorstellen, wo der Kurs dann stehen wird.
Einige NNBP Shares sollte man meiner Meinung nach im Depot haben. Lt. Mr. Silver, Director of Research for Wall Street Resources ist Nanobac`s potentieller Markt 500 Mrd. Dollar schwer. 69% aller OS Aktien werden vom Nanobac-Team selbst gehalten. Quelle:
http://www.wallstreetresources.net/pdf/fc/NNBP.pdf
Auch ohne Erfolgsmeldung wird der Titel meiner Meinung nach, aufgrund der enormen Ertragsmöglichkeiten in einem kurzen Zeitfenster bis auf 50-60 Cent laufen. (Börse handelt die Zukunft).
Der Stochastik generiert ein Kaufsignal. Die Bullen gewinnen an Oberwasser.
Mit American Health Associates wurde eine Übereinkunft geschlossen, um o. g. Testverfahren durchzuführen.
http://biz.yahoo.com/bw/061004/20061004005580.html?.v=1
Mr. Paul Silver, Director of Research for Wall Street Resources, Inc., which contains a short-term target value for NNBP of $0.91 per share.
http://biz.yahoo.com/bw/060912/20060912005464.html?.v=1
http://www.wallstreetresources.net/pdf/fc/NNBP.pdf
Das ist keine Kauf- oder Verkaufsempfehlung. Aktien können fallen oder steigen. Bei Aktienanlagen ist auch in manchen Fällen ein Totalverlust möglich. Übersetzungsfehler behalte ich mir vor, da meine Muttersprache Deutsch ist. Alle Angaben ohne Gewähr. Quellen bitte selbst nochmal nachlesen.
20.10.06 12:03
#2
Nukem
Reizvoll
Der Stochastic hat dreht von ganz unten auf und hat die 25er Linie durchbrochen. Wenn Mr. Silver von 500 Mrd. Marktpotential spricht, dann ist das nur als Beispiel für die ungefähre Größenordnung gedacht. Jeder weiß, dass dass viele Firmen Mittelchen und Wässerchen gegen die verschiedenstens Krankheiten suchen. EIN funktionierender Lösungsansatz stellt dann einen Multi-Blockbuster da.
Aber auch ohne diese Erfolgsmeldung können sich meiner Meinung nach Kurz- u. Mittelfristtrader auf gute Kursgewinne freuen, da alleine die Tatsache, dass Nanobac dieser Multi-Blockbuster gelingt, diese Aktie langfristig im Gespräch halten wird. Gerade jetzt nach der Korrektur und dem erneuten Kaufsingal halte ich das NNBP Einstiegs-Timing aktuell für reizvoll.
Aber auch ohne diese Erfolgsmeldung können sich meiner Meinung nach Kurz- u. Mittelfristtrader auf gute Kursgewinne freuen, da alleine die Tatsache, dass Nanobac dieser Multi-Blockbuster gelingt, diese Aktie langfristig im Gespräch halten wird. Gerade jetzt nach der Korrektur und dem erneuten Kaufsingal halte ich das NNBP Einstiegs-Timing aktuell für reizvoll.
Angehängte Grafik:
nnbp.gif (verkleinert auf 63%)
nnbp.gif (verkleinert auf 63%)
20.10.06 12:11
#3
Nukem
Wissenschaft.
Ein Fachartikel. Es gibt aber viele.
Tree of life, divided between three major cell types, those with and without a nucleus (Bacterial Prokaryotes and Animal Eukaryotes), preceded by the root of the tree, Archea.
an Astrobiology Magazine Interview with Lynn Margulis, Part III
Moffett Field CA (SPX) Oct 10, 2006
Lynn Margulis and Dorion Sagan first published the controversial book Microcosmos: Four Billion Years of Microbial Evolution, in 1986. Although many of the ideas in Microcosmos are now widely accepted, Margulis is still a controversial figure in the biological sciences.
In this, the third in a four-part interview with Astrobiology Magazine, she explains why she believes that the notion of species doesn\'t apply to bacteria, and why she rejects the separation of Archaea into a different domain of life from Bacteria.
Astrobiology Magazine: You have argued that bacteria don\'t have species. I wonder if you could explain that idea.
Lynn Margulis: Bacteria are much more of a continuum. They drop their genes all the time. Like we say in What is Life?, it\'s like going swimming in a swimming pool, going in blue-eyed and coming out brown-eyed, just because you\'ve gulped the water. Obviously, animals don\'t do that. But that\'s what bacteria do, all the time. They just pick up genes, they throw away genes, and they are very flexible about that.
Say you have a bacterium like Azotobacter. This is a nitrogen-fixing bacterium. It takes nitrogen out of the air and puts it into useable food. Nitrogen fixing is a big deal. It takes a lot of genes. If you put a little something like arsenium bromide in a test tube with these organisms, and put it in a refrigerator overnight, lo and behold, the next day the cells can\'t do this anymore, they can\'t fix nitrogen. So by definition you have to change them from one genus to another.
I\'ll give you another example: E. coli. It\'s a normal inhabitant of the human gut. If you put a particular plasmid into E. coli, all of a sudden you have Klebsiella and not E. coli. You\'ve changed not only the species, but the genus. It\'s like changing a person to a chimpanzee. Can you imagine doing that, putting a chimpanzee in the refrigerator, and getting him out the next morning, and now he\'s a person?
Sorin Sonea, who was the chair of the microbiology department at the Université de Montreal, in Canada, has been saying for 25 or 30 years that you either have to consider all the bacteria on Earth as one species, or you have to consider them as no species at all. The criteria we use for species, which are good ones for animals and plants and fungi, do not apply, because bacteria can change overnight. You have all sorts of gradations, where adding or removing a few genes will change an organism\'s name, because those genes are what define the organism.
For example, Agrobacterium causes tumors on the crown of a plant, where the soil meets the base of the plant. If you get rid of just one plasmid, Agrobacterium can\'t make the tumor anymore. So it\'s now got a new name, by definition. So you\'ve got this terrifically arbitrary situation.
But microbiology\'s mostly not science, it\'s practical art. That comes from its beginnings with Pasteur. Microbiologists are pragmatic, pious businessmen. There\'s no intellectual tradition in microbiology.
Bacteria do not have species. The rules for species naming do not apply to bacteria. But they need to have identity labels because of the practical importance in agriculture and health.
AM: So what would you call them, these different microbial organisms?
LM: You\'d call them bacterial strains, or something like that. They definitely have some kind of identity. The genus name is more important than the species name. The genus name does correlate with a lot of common traits. But the reason the species were imposed is because they\'re socially so important, they\'re economically so important, that you can\'t have total chaos. You have to have a name, just like you have to have a name for diseases. How can you treat them if you don\'t have a name?
When you get to any eukaryotic organism, a species is a meaningful term. It represents the entire group. Species are discontinuous and distinct in the eukaryotes. But they\'re just not in bacteria. It\'s a continuum.
AM: Carl Woese in the late 1970s discovered a group of microorganisms that he named Archaea, and he drew a new tree of life, in which the major subdivisions were three domains - Archaea, Bacteria and Eukarya - rather than five kingdoms. But you like the five-kingdoms approach better. That was a surprise to me, because it was in part Woese\'s redrawing of the tree that helped bring the importance of microbes to more general awareness.
LM: Okay. I think that\'s a really crucial thing.
The first thing to say is that Woese made an unprecedented contribution, because he\'s got a single gene, namely the one for 16S RNA, which is present in all cells - because they don\'t work otherwise. And that gene can be compared in all organisms, whether they have feathers or teeth, or leaves, or spores, or whatever it is. That gives you what the 19th century people called a "partial phylogeny." It gives you a trait that can be traced through every cellular organism.
By tracing that gene he found that there are these two major groups of bacteria, and then most of the eukaryotes are relatively uniform with respect to this one trait. That\'s so far, so good. But he\'s worse than wrong about taking that trait as representing the live organism and the organism\'s history. That\'s where there\'s a horrible problem.
And the problem is that you\'ve only got one gene. But an organism has 30,000 genes (if it\'s a eukaryote), and he\'s ignoring 29,999. (If it\'s a prokaryote, it typically has 5 or 6 thousand genes.) So you\'re not studying the lineage of live organisms when you study this gene. You\'re studying this gene.
Now this gene does give you an insight, and I would not deny that.
If Woese had not seen the differences between Archaebacteria and Eubacteria, I wouldn\'t have been able to see that all eukaryotes have both types in their ancestry, and therefore are products of symbiogenesis. It\'s a very valid point.
And being able to quickly assess what kind of bacteria an organism is with respect to this 16S RNA, all of that\'s very useful and very practical. And very informative. But what he\'s done is extrapolated it way beyond what it\'s really telling you. What amazes me is how fast people accepted this. Archaebacteria can exchange genes with Eubacteria. They are bacteria in every way.
http://www.terradaily.com/reports/Bacteria_Do_Not_Have_Speci…
Tree of life, divided between three major cell types, those with and without a nucleus (Bacterial Prokaryotes and Animal Eukaryotes), preceded by the root of the tree, Archea.
an Astrobiology Magazine Interview with Lynn Margulis, Part III
Moffett Field CA (SPX) Oct 10, 2006
Lynn Margulis and Dorion Sagan first published the controversial book Microcosmos: Four Billion Years of Microbial Evolution, in 1986. Although many of the ideas in Microcosmos are now widely accepted, Margulis is still a controversial figure in the biological sciences.
In this, the third in a four-part interview with Astrobiology Magazine, she explains why she believes that the notion of species doesn\'t apply to bacteria, and why she rejects the separation of Archaea into a different domain of life from Bacteria.
Astrobiology Magazine: You have argued that bacteria don\'t have species. I wonder if you could explain that idea.
Lynn Margulis: Bacteria are much more of a continuum. They drop their genes all the time. Like we say in What is Life?, it\'s like going swimming in a swimming pool, going in blue-eyed and coming out brown-eyed, just because you\'ve gulped the water. Obviously, animals don\'t do that. But that\'s what bacteria do, all the time. They just pick up genes, they throw away genes, and they are very flexible about that.
Say you have a bacterium like Azotobacter. This is a nitrogen-fixing bacterium. It takes nitrogen out of the air and puts it into useable food. Nitrogen fixing is a big deal. It takes a lot of genes. If you put a little something like arsenium bromide in a test tube with these organisms, and put it in a refrigerator overnight, lo and behold, the next day the cells can\'t do this anymore, they can\'t fix nitrogen. So by definition you have to change them from one genus to another.
I\'ll give you another example: E. coli. It\'s a normal inhabitant of the human gut. If you put a particular plasmid into E. coli, all of a sudden you have Klebsiella and not E. coli. You\'ve changed not only the species, but the genus. It\'s like changing a person to a chimpanzee. Can you imagine doing that, putting a chimpanzee in the refrigerator, and getting him out the next morning, and now he\'s a person?
Sorin Sonea, who was the chair of the microbiology department at the Université de Montreal, in Canada, has been saying for 25 or 30 years that you either have to consider all the bacteria on Earth as one species, or you have to consider them as no species at all. The criteria we use for species, which are good ones for animals and plants and fungi, do not apply, because bacteria can change overnight. You have all sorts of gradations, where adding or removing a few genes will change an organism\'s name, because those genes are what define the organism.
For example, Agrobacterium causes tumors on the crown of a plant, where the soil meets the base of the plant. If you get rid of just one plasmid, Agrobacterium can\'t make the tumor anymore. So it\'s now got a new name, by definition. So you\'ve got this terrifically arbitrary situation.
But microbiology\'s mostly not science, it\'s practical art. That comes from its beginnings with Pasteur. Microbiologists are pragmatic, pious businessmen. There\'s no intellectual tradition in microbiology.
Bacteria do not have species. The rules for species naming do not apply to bacteria. But they need to have identity labels because of the practical importance in agriculture and health.
AM: So what would you call them, these different microbial organisms?
LM: You\'d call them bacterial strains, or something like that. They definitely have some kind of identity. The genus name is more important than the species name. The genus name does correlate with a lot of common traits. But the reason the species were imposed is because they\'re socially so important, they\'re economically so important, that you can\'t have total chaos. You have to have a name, just like you have to have a name for diseases. How can you treat them if you don\'t have a name?
When you get to any eukaryotic organism, a species is a meaningful term. It represents the entire group. Species are discontinuous and distinct in the eukaryotes. But they\'re just not in bacteria. It\'s a continuum.
AM: Carl Woese in the late 1970s discovered a group of microorganisms that he named Archaea, and he drew a new tree of life, in which the major subdivisions were three domains - Archaea, Bacteria and Eukarya - rather than five kingdoms. But you like the five-kingdoms approach better. That was a surprise to me, because it was in part Woese\'s redrawing of the tree that helped bring the importance of microbes to more general awareness.
LM: Okay. I think that\'s a really crucial thing.
The first thing to say is that Woese made an unprecedented contribution, because he\'s got a single gene, namely the one for 16S RNA, which is present in all cells - because they don\'t work otherwise. And that gene can be compared in all organisms, whether they have feathers or teeth, or leaves, or spores, or whatever it is. That gives you what the 19th century people called a "partial phylogeny." It gives you a trait that can be traced through every cellular organism.
By tracing that gene he found that there are these two major groups of bacteria, and then most of the eukaryotes are relatively uniform with respect to this one trait. That\'s so far, so good. But he\'s worse than wrong about taking that trait as representing the live organism and the organism\'s history. That\'s where there\'s a horrible problem.
And the problem is that you\'ve only got one gene. But an organism has 30,000 genes (if it\'s a eukaryote), and he\'s ignoring 29,999. (If it\'s a prokaryote, it typically has 5 or 6 thousand genes.) So you\'re not studying the lineage of live organisms when you study this gene. You\'re studying this gene.
Now this gene does give you an insight, and I would not deny that.
If Woese had not seen the differences between Archaebacteria and Eubacteria, I wouldn\'t have been able to see that all eukaryotes have both types in their ancestry, and therefore are products of symbiogenesis. It\'s a very valid point.
And being able to quickly assess what kind of bacteria an organism is with respect to this 16S RNA, all of that\'s very useful and very practical. And very informative. But what he\'s done is extrapolated it way beyond what it\'s really telling you. What amazes me is how fast people accepted this. Archaebacteria can exchange genes with Eubacteria. They are bacteria in every way.
http://www.terradaily.com/reports/Bacteria_Do_Not_Have_Speci…
20.10.06 12:28
#4
Nukem
Phantasie
Auch ohne den Erfolg einer Zulassung sollte NNBP alleine durch die Phantasie (und Charttechnik) bis auf 60 Cent getragen werden. Ich will gar nicht darauf spekulieren, dass NNBP den Durchbruch tatsächlich schafft, dann wäre der Titel das XXXXX - fache wert.
20.10.06 12:34
#5
Calibra21
Hi Nukem
Im anderen NNBP - Thread habe ich bereits daraufhingewiesen dass NNBP die zweite Glif werden könnte! So wie ich das gelesen habe entwickeln die auch Tests.
20.10.06 12:41
#6
Nukem
Test
Ja, die Test laufen hinsichtlich infektiöser Erreger, welche in der Lage sind sich selbst rezuproduzieren.
Wer auf eine Zulassung spekuliert, hat entweder den XXXX-fachen Einsatz (sprengt jede Vorstellungskraft). Auch wenn es Probleme geben sollte, NNBP hat jede Menge Patente. Die Pharmariesen sind sicherlich nicht abgeneigt hier mal einen Kauf zu tätigen.
Aber zumindest kurz und mittelfristig hat NNBP deutliches Potential.
Wer auf eine Zulassung spekuliert, hat entweder den XXXX-fachen Einsatz (sprengt jede Vorstellungskraft). Auch wenn es Probleme geben sollte, NNBP hat jede Menge Patente. Die Pharmariesen sind sicherlich nicht abgeneigt hier mal einen Kauf zu tätigen.
Aber zumindest kurz und mittelfristig hat NNBP deutliches Potential.
20.10.06 12:45
#7
Nukem
Tradingchance.
Wenigstens einer mit Weitblick für Tradingschancen hier.....
Nein, Timing is alles und jetzt scheint es soweit zu sein.
Nein, Timing is alles und jetzt scheint es soweit zu sein.
21.10.06 09:54
#8
Calibra21
Um hier das gigantische Potenzial zu erkennen
muss man die letzten News "zerstückelt" aufarbeiten. Um was geht es primär?
Es geht in erster Linie um die sog. "Calcifying Nanoparticle (CNP)". Auf deutsch: "verkalkende Nanopartikel".
Diese CNP sollen lt. NNBP für zahlreiche Krankheiten verantwortlich sein. Beispielsweise Nieren- und Gallensteine oder Arteriosklerose. Auf dem linken Bild sieht man die Ablagerungen unter´m Mikroskop. Auf dem rechten Bild die lt. NNBP dafür verantwortliche Nanobakterielle Kultur.
Es geht in erster Linie um die sog. "Calcifying Nanoparticle (CNP)". Auf deutsch: "verkalkende Nanopartikel".
Diese CNP sollen lt. NNBP für zahlreiche Krankheiten verantwortlich sein. Beispielsweise Nieren- und Gallensteine oder Arteriosklerose. Auf dem linken Bild sieht man die Ablagerungen unter´m Mikroskop. Auf dem rechten Bild die lt. NNBP dafür verantwortliche Nanobakterielle Kultur.
Angehängte Grafik:
NNBP.jpg (verkleinert auf 87%)
NNBP.jpg (verkleinert auf 87%)
21.10.06 19:38
#9
Calibra21
Nanobac ist ein Pioneer in diesem Markt,
der 500 Milliarden schwer ist !!!
...Nanobac’s market is immense considering the potential market for diagnostic and therapeutics for calcific diseases, which we estimate to exceed $500 billion per year...
Die Test´s um die CNP´s ausfindig zu machen existieren bereits! (Diagnostik)
...Nanobac offers IVD kits and reagents for detection of calcifying nano-particles...
Produkte für die Therapie sollen 2007 kommen. ...Nanobac expects to have a therapeutic on the market by the end of 2007 or the beginning of 2008...
Das Marktpotenzial ist unvorstellbar. Und NNBP hat bereits Test´s in der Pipeline.
http://www.wallstreetresources.net/pdf/fc/NNBP.pdf
...Nanobac’s market is immense considering the potential market for diagnostic and therapeutics for calcific diseases, which we estimate to exceed $500 billion per year...
Die Test´s um die CNP´s ausfindig zu machen existieren bereits! (Diagnostik)
...Nanobac offers IVD kits and reagents for detection of calcifying nano-particles...
Produkte für die Therapie sollen 2007 kommen. ...Nanobac expects to have a therapeutic on the market by the end of 2007 or the beginning of 2008...
Das Marktpotenzial ist unvorstellbar. Und NNBP hat bereits Test´s in der Pipeline.
http://www.wallstreetresources.net/pdf/fc/NNBP.pdf
22.10.06 03:15
#10
fritz01
nanobac ? YES !
DER nanobacteria-Guru, der Finne Olavi Kajander (Kajander-hp bzw. allg. wikipedia zum Thema), gehoert zum Management von nanobac (nanobac).
nanotec wird immer mehr der absolute hype:
- typisch dafuer: nanogate (nanogate ag), "enabler" der Nanotechnologie in D, hatte vorige Woche die chuspe, mit einem Emmissionspreis von 32 Euro (!, bei einem kgv von 36,8) in Frankfurt (entry standard) einzusteigen (ard) - und nanogate (isin DE000A0JKHC9) wurde bis jetzt noch nicht geschlachtet, im Gegenteil !
- die eu foerdert (i.U. zum damals verschlafenen biotec-boom) von Anfang an die nano-welle (cordis) - trotz unvorhersehbarem Risiko.
Momentan feiert vor allem die Materialtechnologie praktische nanotec-Erfolge, in der Medizin besteht aber ein mindestens ebenso grosser Bedarf: "plaque"-Krankheiten wie Arteriosklerose oder Herz-Kranz-Gefaess-Krankheiten (haben nukem und calibra schon erwaehnt), aber auch z.B. ms (multiple Sklerose, bei der bis jetzt ueberhaupt keine sinnvollen Therapien existieren), koennten effektiv bekaempft werden.
Fuer mich gibt's nur ein Fragezeichen: gehoert es mittlerweile zur Strategie von ciba/novartis etc., kleine Firmen erstmal vorpreschen zu lassen ?
nanotec wird immer mehr der absolute hype:
- typisch dafuer: nanogate (nanogate ag), "enabler" der Nanotechnologie in D, hatte vorige Woche die chuspe, mit einem Emmissionspreis von 32 Euro (!, bei einem kgv von 36,8) in Frankfurt (entry standard) einzusteigen (ard) - und nanogate (isin DE000A0JKHC9) wurde bis jetzt noch nicht geschlachtet, im Gegenteil !
- die eu foerdert (i.U. zum damals verschlafenen biotec-boom) von Anfang an die nano-welle (cordis) - trotz unvorhersehbarem Risiko.
Momentan feiert vor allem die Materialtechnologie praktische nanotec-Erfolge, in der Medizin besteht aber ein mindestens ebenso grosser Bedarf: "plaque"-Krankheiten wie Arteriosklerose oder Herz-Kranz-Gefaess-Krankheiten (haben nukem und calibra schon erwaehnt), aber auch z.B. ms (multiple Sklerose, bei der bis jetzt ueberhaupt keine sinnvollen Therapien existieren), koennten effektiv bekaempft werden.
Fuer mich gibt's nur ein Fragezeichen: gehoert es mittlerweile zur Strategie von ciba/novartis etc., kleine Firmen erstmal vorpreschen zu lassen ?
22.10.06 03:56
#11
fritz01
err wikipedia und Olavi Kajander
http://de.wikipedia.org/wiki/Nanobakterien
http://de.wikipedia.org/wiki/Nanobakterien
22.10.06 10:05
#12
Calibra21
Nochmals zu den Test´s :
Es existieren momentan zwei Tests. Diese Test´s wurden von der FDA NOCH NICHT genehmigt. Die Betonung liegt auf "nocht nicht".
...Nanobac has developed two diagnostic test kits for the detection of nanobacteria antibodies and antigens. The NB2 ELISA* kits are intended for the quantitative detection of CNP particulate antigen in human serum or EDTA-plasma, and for antibodies produced by the human body against the CNPs/nanobacteria...
[*Testing performed by Nanobac Oy, Clinical Laboratory, Kuopio, Finland. This test was developed and its characteristics determined by Nanobac Oy. It has not been cleared or approved by the US FDA.]
http://www.nanobaclabs.com/content/diagnostics.htm
...Nanobac has developed two diagnostic test kits for the detection of nanobacteria antibodies and antigens. The NB2 ELISA* kits are intended for the quantitative detection of CNP particulate antigen in human serum or EDTA-plasma, and for antibodies produced by the human body against the CNPs/nanobacteria...
[*Testing performed by Nanobac Oy, Clinical Laboratory, Kuopio, Finland. This test was developed and its characteristics determined by Nanobac Oy. It has not been cleared or approved by the US FDA.]
http://www.nanobaclabs.com/content/diagnostics.htm
22.10.06 11:19
#13
Calibra21
Gehen wir mal ins "Eingemachte"
Im Jahr 2006 wird man lt. der Analyse ( http://www.wallstreetresources.net/pdf/fc/NNBP.pdf )ca. 2 Cent Verlust pro Aktie machen. Im Jahr 2009 erwarten die Analysten einen Gewinn ja Aktie von über 20 Cent!!! D.h., der Aktienkurs müsste sich mehr als verzehnfachen!
23.10.06 12:57
#14
Nukem
500 000 000 000
Verzehnfachen? Ein guten klinischen Resultaten wird AAGH sich mehr als verzehnfachen. Wir sprechen hier von einem Markt der im JAHR 500 000 000 000 Dollar schwer ist. Pro Jahr. Selbst wenn AAGH nur mit dem Umsatz bewertet wäre, sprengt das alles Vorstellbare.
Ok, immer Pelle flachhalten. Lieber konservativer posten. klar. Ich will nur mal rausstellen dass NNBP eine Megagranaten-Chance ist.
Ok, immer Pelle flachhalten. Lieber konservativer posten. klar. Ich will nur mal rausstellen dass NNBP eine Megagranaten-Chance ist.
23.10.06 13:09
#15
Nukem
NNBP
NNBP natürlich.. AAGH is auch megainteressant, aber darum gehts hier nicht. Sorry, ich meinte natürlich NNBP. :)
24.10.06 10:28
#16
Nukem
Rückschlagspotential begrenzt.
Das Rückschlagspotetial halte ich für sehr begrenzt.
24.10.06 19:33
#17
Nukem
News!
Nanobac Pharmaceuticals Partners with Health Care Communications Firm
Tuesday October 24, 12:52 pm ET
TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP - News) has enlisted The Aker Partners Inc. to implement a comprehensive national media relations program.
ADVERTISEMENT
Nanobac is a growing pharmaceutical company in the field of medical nanotechnology. The company\'s focus is on developing methods to treat calcifying nanoparticles (CNPs), and by doing so, find more effective approaches to treating and preventing the cardiovascular, kidney and prostate diseases associated with them.
"Nanobac is deep into landmark medical research that we believe will redefine the way we view disease and change the way physicians approach the treatment of illnesses," said Nanobac Co-Chairman Dr. Benedict Maniscalco. "We believe utilizing the experienced professionals at The Aker Partners will not only increase the visibility of our work in the field of medical nanotechnology, but also enhance the viability of our company."
Nanotechnology is the realm of discovering and exploiting the special characteristics of materials at the atomic scale. A nanoparticle is generally considered to be anything less than 100 nanometers, or 100 billionths of a meter. If a one-meter ruler could be stretched from New York City to Los Angeles, a nanometer on that ruler would still be only the size of an aspirin.
The specialized type of medical nanotechnology being pursued by Nanobac aims to combat disease on that "nano" scale by detecting calcifying nanoparticles that straddle the 100 nanometer size line, ranging in diameter from 75 nm to more than 500 nm. Researchers believe these CNPs are the basic cause of a multitude of illnesses.
Based in Washington, D.C., The Aker Partners is a specialist in the health care industry and has broad experience in the rapidly growing field of medical nanotechnology. The agency has engineered successful communications campaigns for companies utilizing nanotechnology and is at the forefront of the effort to educate the public about the positive medical implications of the technology.
"Over the last 24 years our firm has helped more than 500 clients tell their compelling stories and communicate their accomplishments," said Aker Partners Manager Partner Colburn Aker. "The breakthroughs occurring at Nanobac are some of the most unique stories we have ever had the opportunity to help communicate."
Nanobac Pharmaceuticals:
Nanobac Pharmaceuticals Inc., based in Tampa, FL, is dedicated to the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). The company\'s pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in prostate, gall bladder and vascular disease. Nanobac\'s drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac\'s BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials. For details visit http://www.nanobac.com.
The Aker Partners Inc.
Since its founding in 1983, Washington-based The Aker Partners has represented more than 500 clients, providing public affairs, health care and marketing communications, plus its trademarked NetPR® Internet communications service. It is the nation\'s only Partner-Directed Communications and Marketing® firm and also serves as the Washington office of the Public Relations Global Network Inc.,® which offers clients more than 50 offices worldwide. For more information, visit www.akerpartners.com.
Contact:
Nanobac Pharmaceuticals Inc., Tampa
Douglas Mulhall, 813-264-2241
dmulhall@nanobaclabs.com
or
Jens Dalsgaard, 415-884-0348
Source: Nanobac Pharmaceuticals Inc.
Tuesday October 24, 12:52 pm ET
TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP - News) has enlisted The Aker Partners Inc. to implement a comprehensive national media relations program.
ADVERTISEMENT
Nanobac is a growing pharmaceutical company in the field of medical nanotechnology. The company\'s focus is on developing methods to treat calcifying nanoparticles (CNPs), and by doing so, find more effective approaches to treating and preventing the cardiovascular, kidney and prostate diseases associated with them.
"Nanobac is deep into landmark medical research that we believe will redefine the way we view disease and change the way physicians approach the treatment of illnesses," said Nanobac Co-Chairman Dr. Benedict Maniscalco. "We believe utilizing the experienced professionals at The Aker Partners will not only increase the visibility of our work in the field of medical nanotechnology, but also enhance the viability of our company."
Nanotechnology is the realm of discovering and exploiting the special characteristics of materials at the atomic scale. A nanoparticle is generally considered to be anything less than 100 nanometers, or 100 billionths of a meter. If a one-meter ruler could be stretched from New York City to Los Angeles, a nanometer on that ruler would still be only the size of an aspirin.
The specialized type of medical nanotechnology being pursued by Nanobac aims to combat disease on that "nano" scale by detecting calcifying nanoparticles that straddle the 100 nanometer size line, ranging in diameter from 75 nm to more than 500 nm. Researchers believe these CNPs are the basic cause of a multitude of illnesses.
Based in Washington, D.C., The Aker Partners is a specialist in the health care industry and has broad experience in the rapidly growing field of medical nanotechnology. The agency has engineered successful communications campaigns for companies utilizing nanotechnology and is at the forefront of the effort to educate the public about the positive medical implications of the technology.
"Over the last 24 years our firm has helped more than 500 clients tell their compelling stories and communicate their accomplishments," said Aker Partners Manager Partner Colburn Aker. "The breakthroughs occurring at Nanobac are some of the most unique stories we have ever had the opportunity to help communicate."
Nanobac Pharmaceuticals:
Nanobac Pharmaceuticals Inc., based in Tampa, FL, is dedicated to the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). The company\'s pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in prostate, gall bladder and vascular disease. Nanobac\'s drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac\'s BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials. For details visit http://www.nanobac.com.
The Aker Partners Inc.
Since its founding in 1983, Washington-based The Aker Partners has represented more than 500 clients, providing public affairs, health care and marketing communications, plus its trademarked NetPR® Internet communications service. It is the nation\'s only Partner-Directed Communications and Marketing® firm and also serves as the Washington office of the Public Relations Global Network Inc.,® which offers clients more than 50 offices worldwide. For more information, visit www.akerpartners.com.
Contact:
Nanobac Pharmaceuticals Inc., Tampa
Douglas Mulhall, 813-264-2241
dmulhall@nanobaclabs.com
or
Jens Dalsgaard, 415-884-0348
Source: Nanobac Pharmaceuticals Inc.
24.10.06 19:34
#18
Nukem
Volumen zieht an!
Umsatz und Kurs ziehen an. Yeah. Die ersten Handelsstunden war nix los, aber jetzt dafür.
24.10.06 19:45
#19
Nukem
Die machen dass hier:
http://www.akerpartners.com/
24.10.06 19:55
#20
Nukem
PR für NNBP!
Who ist who der Wirtschafskonzerne... Honeywell, Ford, Rolls Royce
Wenn man das liest, was die Kunden über die PR-Agentur sagen, dann liest sich dass ganz gut. Verkaufssteigerungen über 260% usw. Sogar Ford hatte seinen Hybrid rausputzen lassen. Interessant.
Vielleicht funktionierts ja auch bei NNBP.
netPr
There were only 16 shopping days until Christmas and Geezer.com, the first Web site selling the crafts of senior artisans badly needed publicity. In order to attract potential holiday buyers, we launched a netPR® campaign, increasing sales by more than 260%.
Für Ford wurde der Hybrid rausgekehrt.
Interessanter Link:
http://www.akerpartners.com/success.html
Wenn man das liest, was die Kunden über die PR-Agentur sagen, dann liest sich dass ganz gut. Verkaufssteigerungen über 260% usw. Sogar Ford hatte seinen Hybrid rausputzen lassen. Interessant.
Vielleicht funktionierts ja auch bei NNBP.
netPr
There were only 16 shopping days until Christmas and Geezer.com, the first Web site selling the crafts of senior artisans badly needed publicity. In order to attract potential holiday buyers, we launched a netPR® campaign, increasing sales by more than 260%.
Für Ford wurde der Hybrid rausgekehrt.
Interessanter Link:
http://www.akerpartners.com/success.html
25.10.06 07:23
#21
Nukem
260% Revenuesteigerung bei Akerpartners Kunden
Folgende Dienstleistungen steht auf deren Liste dieser PR-Firma: Gut sind sie, zufriedene Kunden teilen auf der Website mit, den Umsatz mit dem akerparnter Marketing bis zu 260% gesteigert zu haben.
* Direct Response Public Relations(DRPR)
* Healthcare
* Marketing Communications
* netPR®
* Public Affairs
* Public Relations
* Technology
* TeamCom 21...Employee Communications
* Direct Response Public Relations(DRPR)
* Healthcare
* Marketing Communications
* netPR®
* Public Affairs
* Public Relations
* Technology
* TeamCom 21...Employee Communications
25.10.06 09:53
#22
Nukem
Strategische Allianzen
Bei den Denkfabriken handelt es sich um folgende: B. Cleveland Clinic, Iowa State University, University of California, Mayo Found. for Medical Education, Washington Hospital und das Miami Hearth Center.
25.10.06 12:12
#23
Nukem
Denkfabriken
Das sind alles Institute, welche sich seit langem mit Herzkreislauf-Erkrankungen beschäftigen.
Mount Sinai Medical Center & Miami Heart Institute is a hospital located at 4300 Alton Road in Miami Beach, Florida, and is the largest independent non-profit teaching hospital in the state. The institution was incorporated on March 11, 1946, and opened on its current location on Sunday, December 4, 1949.
Celebrities treated at Mount Sinai have included Jackie Gleason and Muhammed Ali (whose daughter, Laila Ali, was born there in 1977).
Maurice Gibb a member of the musical group The Bee Gees, passed away in the hospital.
[edit] Reference
Mount Sinai Medical Center & Miami Heart Institute is a hospital located at 4300 Alton Road in Miami Beach, Florida, and is the largest independent non-profit teaching hospital in the state. The institution was incorporated on March 11, 1946, and opened on its current location on Sunday, December 4, 1949.
Celebrities treated at Mount Sinai have included Jackie Gleason and Muhammed Ali (whose daughter, Laila Ali, was born there in 1977).
Maurice Gibb a member of the musical group The Bee Gees, passed away in the hospital.
[edit] Reference
25.10.06 12:14
#24
Nukem
Kurssziel 60 Cent
Washington Hospital
http://www.whcenter.org/
Includes centers providing specialized care for heart disease, cancer, emergencies and women\'s health.
Auf deren Website prangert das Qualitätssiegel Americas best hospitals 2006
Genau wie bei der cleveland clinic
http://www.clevelandclinic.org/
http://www.whcenter.org/
Includes centers providing specialized care for heart disease, cancer, emergencies and women\'s health.
Auf deren Website prangert das Qualitätssiegel Americas best hospitals 2006
Genau wie bei der cleveland clinic
http://www.clevelandclinic.org/
25.10.06 13:02
#25
Nukem
News-flow
Mal sehen wie es heute weiter geht! Ich rechne mit einem weiter positiven News Flow.
Seite:
1